论文部分内容阅读
目的观察低剂量沙利度胺联合化疗治疗多发性骨髓瘤(MM)的疗效及不良反应。方法分析22例初治和8例复发难治MM患者应用低剂量沙利度胺联合化疗治疗的总有效率和不良反应;分析治疗前后患者M蛋白量、骨髓浆细胞比例以及血红蛋白浓度变化情况。结果 30例MM,完全缓解7例,部分缓解7例,微小反应4例,总有效率60%。治疗前后患者M蛋白量、骨髓浆细胞比例以及血红蛋白浓度相比差异有统计学意义(P<0.05)。应用沙利度胺不良反应轻,均可耐受。结论低剂量沙利度胺联合化疗治疗多发性骨髓瘤安全有效。
Objective To observe the efficacy and adverse reactions of low dose thalidomide combined with chemotherapy in the treatment of multiple myeloma (MM). Methods The total effective rate and adverse reactions of 22 patients with untreated MM and 8 patients with relapsed or refractory MM treated with low-dose thalidomide combined with chemotherapy were analyzed. The changes of M protein, ratio of bone marrow plasma cells and hemoglobin before and after treatment were analyzed. Results 30 cases of MM, complete remission in 7 cases, partial remission in 7 cases, 4 cases of minimal response, the total efficiency of 60%. There was significant difference in the amount of M protein, proportion of bone marrow plasma cells and hemoglobin before and after treatment (P <0.05). Adverse reactions to thalidomide are mild and tolerable. Conclusion Low-dose thalidomide combined with chemotherapy for multiple myeloma is safe and effective.